Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BioArctic AB Class B ( ($SE:BIOA.B) ) has issued an update.
BioArctic AB has issued 78,000 new Class B shares in February 2026 to fulfill commitments under its 2019/2028 stock option program, providing equity-based incentives to participants. Following this issuance, the company’s total share count stands at 88,719,485, split between 74,319,489 listed Class B shares and 14,399,996 unlisted Class A shares, underscoring a dual-class structure that concentrates voting power.
The A shares each carry ten votes compared with one vote per B share, bringing the total number of votes in the company to 218,319,449 and maintaining significant control with A share holders. This capital structure update, disclosed under EU Market Abuse Regulation requirements, offers investors and other stakeholders an updated view of BioArctic’s share base and governance dynamics as it advances its neurodegenerative disease portfolio.
The most recent analyst rating on ($SE:BIOA.B) stock is a Buy with a SEK385.00 price target. To see the full list of analyst forecasts on BioArctic AB Class B stock, see the SE:BIOA.B Stock Forecast page.
More about BioArctic AB Class B
BioArctic AB is a Swedish research-based biopharmaceutical company focused on developing innovative treatments to delay or halt the progression of neurodegenerative diseases. The company co-invented Leqembi (lecanemab), the first drug shown to slow disease progression and reduce cognitive impairment in early Alzheimer’s, and it maintains a broad portfolio targeting Alzheimer’s, Parkinson’s-related diseases, and ALS, supported by its proprietary BrainTransporter technology.
BioArctic’s collaboration partner Eisai manages global regulatory interactions and commercialization for Leqembi, while BioArctic continues advancing pipeline antibodies and platform technologies. The company’s Class B share is listed on Nasdaq Stockholm Large Cap under the ticker BIOA B, positioning the firm within the international neurodegenerative disease therapeutics market.
Average Trading Volume: 227,672
Technical Sentiment Signal: Buy
Current Market Cap: SEK28.38B
For detailed information about BIOA.B stock, go to TipRanks’ Stock Analysis page.